UPSC CURRENT AFFAIRS – 14 OCTOBER 2026

GS 2 Towards a TB-Free India

Context: The Ministry of Health and Family Welfare launched the nationwide JOSH (Joint Squad for Health) campaign across 11 states and 55 districts to mobilize youth networks, NCC cadets, and grassroots communities in the push toward a TB-free India.

Towards a TB-Free India

About Towards a TB-Free India :

What is Tuberculosis (TB)?

Tuberculosis is a chronic, communicable airborne infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily attacks the lungs but can disseminate through the bloodstream to infect other organs, spreading via respiratory droplet nuclei when infected individuals cough, sneeze, or speak.

Types of Tuberculosis:

Latent vs. Active TB: Latent (inactive) TB infection occurs when bacteria reside in the body without causing sickness or spreading; active TB develops when the immune system weakens, multiplying bacteria and producing clinical symptoms.

Latent (inactive) TB infection occurs when bacteria reside in the body without causing sickness or spreading; active TB develops when the immune system weakens, multiplying bacteria and producing clinical symptoms. Pulmonary vs. Extra-Pulmonary TB (EPTB): Pulmonary TB affects lung parenchyma and remains contagious, while EPTB infects other biological sites—including the central nervous system (tubercular meningitis), spine (Pott’s disease), lymph nodes, and kidneys—and is generally non-contagious.

Pulmonary TB affects lung parenchyma and remains contagious, while EPTB infects other biological sites—including the central nervous system (tubercular meningitis), spine (Pott’s disease), lymph nodes, and kidneys—and is generally non-contagious. Drug-Susceptible vs. Drug-Resistant TB (DR-TB): Encompasses standard TB treatable with first-line drugs versus Multi-Drug Resistant (MDR-TB resistant to Isoniazid and Rifampicin), Extensively Drug-Resistant (XDR-TB), or Rifampicin-Resistant (RR-TB) strains demanding specialized toxic regimens.

Data / Stats on TB in India:

Incidence and Mortality Decline : Between 2015 and 2024, newly emerging TB cases in India dipped by 21% (against a 12% global reduction), while domestic TB mortality contracted by 28%.

Between 2015 and 2024, newly emerging TB cases in India dipped by 21% (against a 12% global reduction), while domestic TB mortality contracted by 28%. Treatment Coverage Gap: India has achieved a 92% treatment coverage rate, surpassing the global baseline of 78%.

India has achieved a 92% treatment coverage rate, surpassing the global baseline of 78%. High Treatment Success: The national treatment success rate under the intensified TB Mukt Bharat Abhiyaan has risen to 90%, outpacing the global average of 88%.

The national treatment success rate under the intensified TB Mukt Bharat Abhiyaan has risen to 90%, outpacing the global average of 88%. Grassroots Elimination Verification: As of 2026, over 46,118 Gram Panchayats have successfully qualified and received official TB-Free Panchayat certifications.

India and TB: Strategic Posture

Ambitious Elimination Timelines: India formally set its national goal to end TB by 2025—five years ahead of the UN Sustainable Development Goal (SDG 3.3) target of 2030—anchored by the National Strategic Plan (NSP).

India formally set its national goal to end TB by 2025—five years ahead of the UN Sustainable Development Goal (SDG 3.3) target of 2030—anchored by the National Strategic Plan (NSP). The Detect–Treat–Prevent–Build Paradigm: The National Tuberculosis Elimination Programme (NTEP) restructured clinical protocols along four pillars: active case-finding, quality-assured regimens, preventive therapies, and health system scaling.

The National Tuberculosis Elimination Programme (NTEP) restructured clinical protocols along four pillars: active case-finding, quality-assured regimens, preventive therapies, and health system scaling. Shift to Jan Andolan (People’s Movement): Transitioned TB eradication from a vertical, hospital-based medical program into a whole-of-society movement mobilizing elected leaders, private corporations, and student volunteers.

Transitioned TB eradication from a vertical, hospital-based medical program into a whole-of-society movement mobilizing elected leaders, private corporations, and student volunteers. Pioneering Digital & Diagnostics Infrastructure: Houses the world’s largest molecular diagnostic network alongside direct benefit transfer (DBT) platforms that provide nutritional cash assistance.

Initiatives Taken So Far:

Pradhan Mantri TB Mukt Bharat Abhiyaan & Ni-kshay Mitra : A community-supported care initiative wherein 6.77+ lakh registered volunteers provide supplementary nutritional food baskets to patients undergoing prolonged therapy.

A community-supported care initiative wherein 6.77+ lakh registered volunteers provide supplementary nutritional food baskets to patients undergoing prolonged therapy. Direct Benefit Nutritional Cash Transfers (Ni-kshay Poshan Yojana): Provides ₹1,000 monthly financial aid to every notified TB patient, disbursing over ₹4,454 crore to 1.38 crore beneficiaries since 2018.

Provides ₹1,000 monthly financial aid to every notified TB patient, disbursing over ₹4,454 crore to 1.38 crore beneficiaries since 2018. Shorter BPaLM Treatment Regimen: Rolled out the oral, 6-month BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin) for drug-resistant TB, cutting down toxic treatment cycles from 18–24 months.

Rolled out the oral, 6-month BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin) for drug-resistant TB, cutting down toxic treatment cycles from 18–24 months. Advanced AI Triage & Molecular Diagnostic Scaling: Deployed over 500 handheld, AI-powered digital X-ray units (DeepCXR), the AI ‘Khushi’ triage chatbot, smartphone cough acoustics (CATB), and expanded molecular machines (CBNAAT/Truenat) across 9,800+ facilities.

Challenges to TB Eradication:

Private Healthcare Sector Under-Notification: Substantial proportions of symptomatic citizens seek initial care from unorganized private practitioners, risking unnotified, incomplete, and substandard anti-tubercular therapy.

E.g., Informal clinics prescribing irrational, non-standardized antibiotic cocktails for persistent coughs, delaying Truenat testing and accelerating acquired drug resistance.

Nutritional Vulnerability & Undernutrition Feeder Pool: Undernutrition remains the single largest population-attributable risk factor in India, increasing susceptibility to latent bacterial activation.

E.g., Impoverished migrant workers earning daily wages who are unable to sustain the high-protein diets required to tolerate first-line and second-line drug toxicity.

Stigmatization & Delayed Care-Seeking: Deep socio-cultural shame surrounding a TB diagnosis leads to social ostracization, concealment of symptoms, and marital disruption—particularly among young women.

E.g., Rural women concealing bloody sputum or fever out of fear of family separation, presenting to tertiary centers only after advanced lung cavitation.

Geographical and Last-Mile Diagnostic Barriers: Logistical constraints in reaching tribal, hilly, and conflict-prone terrains delay early case-finding and sputum specimen transit.

E.g., High-altitude Himalayan villages in Kashmir’s Gurez valley remaining cut off for months during winter, requiring mobile all-terrain testing vans to prevent transmission.

Way Ahead:

Universalize TB Preventive Treatment (TPT): Scale up preventive chemoprophylaxis regimens (such as weekly rifapentine and isoniazid) to all household contacts, immuno-compromised patients, and slum clusters to sterilize the latent reservoir.

Scale up preventive chemoprophylaxis regimens (such as weekly rifapentine and isoniazid) to all household contacts, immuno-compromised patients, and slum clusters to sterilize the latent reservoir. Mandate Private-Sector Interoperability: Enforce real-time pharmacy and clinical reporting through the Ni-kshay digital portal, tying private drug dispensations directly to Aadhaar-verified notification protocols.

Enforce real-time pharmacy and clinical reporting through the Ni-kshay digital portal, tying private drug dispensations directly to Aadhaar-verified notification protocols. Sub-District Molecular Diagnostic Decentralization : Replace conventional smear microscopy completely by placing indigenous battery-operated Truenat units at every Ayushman Arogya Mandir (AAM).

Replace conventional smear microscopy completely by placing indigenous battery-operated Truenat units at every Ayushman Arogya Mandir (AAM). Institutionalize Airborne Infection Control: Implement mandatory cross-ventilation retrofits, ultraviolet germicidal irradiation (UVGI), and N95 respiratory protection in overcrowded outpatient clinics and prisons.

Implement mandatory cross-ventilation retrofits, ultraviolet germicidal irradiation (UVGI), and N95 respiratory protection in overcrowded outpatient clinics and prisons. Sustain Social Protections Post-Recovery: Expand financial protections beyond clinical cure by offering skill rehabilitation and lung-health impairment pensions to survivors left with chronic fibrotic pulmonary disease.

Conclusion:

India’s public health response to tuberculosis is shifting from a standard disease control framework into an evidence-driven, community-led elimination model. While molecular diagnostics, digital platforms, and shortened drug regimens have achieved notable drops in incidence, eliminating the latent disease reservoir remains a critical hurdle. Fulfilling the vision of a TB-free India will depend on sustaining whole-of-society mobilization, dismantling social stigma, and ensuring nutrition-backed care reaches the most vulnerable citizens.